Page last updated: 2024-09-03

2-pyrrolino-dox and Lymphoma, T-Cell

2-pyrrolino-dox has been researched along with Lymphoma, T-Cell in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ibrahimova, M; Rihova, B; Studenovsky, M; Ulbrich, K	1

Other Studies

1 other study(ies) available for 2-pyrrolino-dox and Lymphoma, T-Cell

Article	Year
Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2011, Jan-18, Volume: 42, Issue:1-2 Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Female; Humans; Lymphoma, T-Cell; Mice; Molecular Structure; Polymethacrylic Acids; Pyrroles; Solubility; Xenograft Model Antitumor Assays	2011

Article

Year

Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2011, Jan-18, Volume: 42, Issue:1-2

Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Female; Humans; Lymphoma, T-Cell; Mice; Molecular Structure; Polymethacrylic Acids; Pyrroles; Solubility; Xenograft Model Antitumor Assays

2011